Author: Business Wire

Aerpio Pharmaceuticals Announces Uplisting to Nasdaq Capital Market and Pricing of $45.0 Million Public Offering of Common Stock

CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO) (“Aerpio”) today announced that its common stock will begin trading on the Nasdaq Capital Market under the symbol “ARPO” at the opening of trading on June 26, 2018, following its previously announced approval to list its common stock on the Nasdaq Capital Market. Aerpio also announced today the pricing of the previously announced underwritten public offering of 11,688,000 shares of its common stock at a price to the public o

STAAR Surgical and Kobe Kanagawa Eye Clinic in Japan Announce Strategic Cooperation Agreement

MONROVIA, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, and Kobe Kanagawa Eye Clinic with locations in Tokyo and Osaka, today announced they have entered into a multi-year Strategic Cooperation Agreement to provide STAAR’s EVO Visian ICL™ lenses as a primary and premium option for patients seeking visual freedom from spectacles and contact lenses through refractive

Aerpio Pharmaceuticals Announces Proposed Public Offering of Common Stock and Uplisting to Nasdaq Capital Market

CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO) (“Aerpio”) today announced that it intends to sell, subject to market and other conditions, $40 million of its common stock in an underwritten public offering. Aerpio also intends to grant the underwriters a 30-day option to purchase an additional fifteen percent (15%) of the shares of its common stock offered in the public offering. Aerpio also announced that its common stock has been approved for listing on the Nasdaq Capi

Glaukos Announces FDA Approval for the iStent inject® Trabecular Micro-Bypass System

SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced it has received premarket approval (PMA) from the U.S. Food and Drug Administration (FDA) for the iStent inject® Trabecular Micro-Bypass System indicated for the reduction of intraocular

New Acucela Data on the Effect of Emixustat Hydrochloride on Retinal Thickness in Diabetic Retinopathy

SEATTLE–(BUSINESS WIRE)–Acucela Inc. (“Acucela”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today new data on the effect of emixustat hydrochloride on retinal thickness in diabetic retinopathy (DR). The study (Protocol 4429-203) is a randomized, placebo-controlled, phase 2 clinical trial exploring the effect of oral emixustat hydrochloride in a proliferative diabetic retinopathy (PDR) population with

China Cancer Drug Market (2018) Size, Trends, Key Opportunities & Forecast to 2022 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “China Cancer Drug Market: Size, Trends & Forecasts (2018-2022)” report has been added to ResearchAndMarkets.com’s offering. The report provides analysis of the China cancer drug market, with detailed analysis of market size and growth, and value of the industry. The analysis includes the market by value, by cases and incidence ratio. Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the

Global Eyewear Market 2017-2018 to 2023: by Product Type, Mode of Sale, Region – Market Size, Demand Forecasts, Company Profiles, Industry Trends and Updates – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Eyewear Market – by Product Type, Mode of Sale, Region – Market Size, Demand Forecasts, Company Profiles, Industry Trends and Updates (2017-2023)” report has been added to ResearchAndMarkets.com’s offering. The glob…